Key result
Anticoagulation is linked to ~64% lower stroke risk vs. antiplatelets in occlusive cervical artery dissection.
Why the study?
Patients with cervical artery dissection are at risk for subsequent ischemic stroke, but characteristics associated with increased risk and the impact of anticoagulant versus antiplatelet therapy remain unclear.
Does anticoagulation compared to antiplatelet therapy reduce subsequent ischemic stroke in patients with cervical artery dissection?
Observational (n=4,023)
Yes
Does anticoagulation compared to antiplatelet therapy reduce subsequent ischemic stroke in patients with cervical artery dissection?
Answers are grounded in this paper and cite their sources.
Anticoagulation may offer a benefit over antiplatelet therapy in reducing subsequent ischemic stroke specifically in patients with cervical artery dissection presenting with occlusive dissection.
BACKGROUND: Patients presenting with cervical artery dissection (CAD) are at risk for subsequent ischemic events. We aimed to identify characteristics that are associated with increased risk of ischemic stroke after initial presentation of CAD and to evaluate the differential impact of anticoagulant versus antiplatelet therapy in these high-risk individuals. METHODS: This was a preplanned secondary analysis of the STOP-CAD study (Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection), a multicenter international retrospective observational study (63 sites from 16 countries in North America, South America, Europe, Asia, and Africa) that included patients with CAD predominantly between January 2015 and June 2022. The primary outcome was subsequent ischemic stroke by day 180 after diagnosis. Clinical and imaging variables were compared between those with versus without subsequent ischemic stroke. Significant factors associated with subsequent stroke risk were identified using stepwise Cox regression. Associations between subsequent ischemic stroke risk and antithrombotic therapy type (anticoagulation versus antiplatelets) among patients with identified risk factors were explored using adjusted Cox regression. RESULTS: In all, 4023 patients (mean age was 47.4 years; 44.5% were women) were included. By day 180, subsequent ischemic stroke occurred in 5.3% of the cohort. In adjusted Cox regression, factors associated with increased risk of subsequent ischemic stroke were prior history of ischemic stroke (adjusted hazard ratio [aHR], 7.31 [95% CI, 1.61–33.13]; P =0.010), presentation within 7 days from first symptoms (aHR, 3.04 [95% CI, 1.04–8.91]; P =0.043), infarct on baseline imaging (aHR, 9.85 [95% CI, 3.65–26.58]; P <0.001), and occlusive dissection (aHR, 2.34 [95% CI, 1.03–5.34]; P =0.043). Only patients with occlusive dissection demonstrated a reduced risk of subsequent ischemic stroke when treated with anticoagulation versus antiplatelets (aHR, 0.36 [95% CI, 0.16–0.80]; P =0.01). CONCLUSIONS: In this post hoc analysis of the STOP-CAD study, several factors associated with subsequent ischemic stroke were identified among patients with CAD. Furthermore, we identified a potential benefit of anticoagulation in patients with CAD with occlusive dissection. These findings require validation by meta-analyses of prior studies to formulate optimal treatment strategies for specific high-risk CAD subgroups.
No takes yet. Share an insight, caveat, or question.
Mandel et al. (2025) conducted an observational in Cervical artery dissection (n=4,023). Anticoagulation vs. Antiplatelets was evaluated on Subsequent ischemic stroke by day 180 (aHR 0.36, 95% CI 0.16-0.80, p=0.01). In patients with cervical artery dissection and occlusive dissection, anticoagulation was associated with a reduced risk of subsequent ischemic stroke compared to antiplatelets.
Synapse has enriched 10 related papers. Consider them for comparative context: